The effects of dobutamine on heart function in patients with enlargement of the heart

The effect of dobtutamin on postoperative systolic deformation and diastolic function in patients with concentric hypertrophy of the left ventricle

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-001005-27-DK

Enrollment

Unknown

Registered

2011-04-19

Start date

2011-05-02

Completion date

Unknown

Last updated

2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis Diastolic dysfunction MedDRA version: 14.1 Level: LLT Classification code 10002907 Term: Aortic stenosis & incompetence System Organ Class: 10007541 - Cardiac disorders

Interventions

Trade Name: Dobutrex Product Name: Dobutrex Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: DOBUTAMINE HYDROCHLORIDE CAS Number: 52663817 Current Sponsor code: 1818 Oth

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible for operation for aortic stenosis Normal EF Left ventrilar hypertrophy Sinus rythm Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 5 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: Concomitant bypass operation Severe mitral valve insufficiency beta-blockade

Design outcomes

Primary

Measure	Time frame
Main Objective: To clarify the hemodynamic effect of low-dose dobutamine on systolic and diastolic cardiac function.;Secondary Objective: Echocardiographic indices of systolic function Echocardiographic indices of diastolic function Mixed venous saturation Heart rate;Primary end point(s): Cardiac index;Timepoint(s) of evaluation of this end point: 0, 90 and 180 minutes	—

Secondary

Measure	Time frame
Secondary end point(s): Echocardiography Invasive measurements.;Timepoint(s) of evaluation of this end point: 0, 90 and 180 minutes	—

Countries

Denmark

Contacts

Public ContactDepartment of Anaesthesia

Århus University Hospital, Skejby

peter.juhl-olsen@yahoo.dk4589498750

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026